The incidence of pancreatic ductal adenocarcinoma (PDAC) has been increasing over the past few decades and survival rates for patients with this malignancy remain dismal. The authors of this Perspective discuss
fixed-duration monotherapy with daratumumab over observation in patients with high-risk smouldering multiple myeloma, which changes the early interception treatment landscape. Herein, we discuss how future studies could build on this success and pave the way to eradicating multiple myeloma before it ...
multiple myelomaEffective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules...
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma June 3, 2025 Early results fromJohnson & Johnson’s trispecific antibody show promising response in heavily pretreated...
Molecular glue degraders such as pomalidomide and lenalidomide have demonstrated remarkable clinical success in treating hematological malignancies including multiple myeloma, and certain lymphomas. In addition to molecular glue, a lot of the recent efforts have been focused on developing PROTACs to overcome...
CancerFax helps late-stage advanced cancer patients access cutting-edge therapies and trials worldwide. CancerFax provides expert guidance.
Categories Multiple Myeloma Innovative treatments give hope to patients with blood cancer By HealthClot Moderator May 23, 2023 0 Innovative treatments give hope to patients with blood cancer Dr. Leslie and Michael speak about CAR T-cell therapies for cancers like LBCL and how eligible patients...
Go to: ’An Overview of Leukemia cancer - symptoms causes and alternative treatments 2024 Research Pesticides and Herbicides as cancer-causing as smoking Natural Compounds and alternative treatments for leukaemia Iodine and cancer CoQ10 and cancer Why you should change your diet, whatever the oncolog...
For patients achiev- ing a CR, the median duration of response (DOR) was 20.5 months, with 5-year progression-free survival (PFS) and overall survival (OS) rates of 52% and 64%, respec- tively. The most common side effects related to the drug were peripheral neuropathy (PN), ...
The prognosis of cancer patients is most influenced by the type of cancer, as well as the stage, or extent of the disease. In addition, histologic grading and the presence of specific molecular markers can also be useful in establishing prognosis, as well as in determining individual treatments...